toxins Review The Search for Natural and Synthetic Inhibitors That Would Complement Antivenoms as Therapeutics for Snakebite Envenoming José María Gutiérrez 1,* , Laura-Oana Albulescu 2, Rachel H. Clare 2, Nicholas R. Casewell 2 , Tarek Mohamed Abd El-Aziz 3,4 , Teresa Escalante 1 and Alexandra Rucavado 1 1 Facultad de Microbiología, Instituto Clodomiro Picado, Universidad de Costa Rica, San José 11501, Costa Rica;
[email protected] (T.E.);
[email protected] (A.R.) 2 Centre for Snakebite Research & Interventions, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK;
[email protected] (L.-O.A.);
[email protected] (R.H.C.);
[email protected] (N.R.C.) 3 Zoology Department, Faculty of Science, Minia University, El-Minia 61519, Egypt;
[email protected] 4 Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900, USA * Correspondence:
[email protected] Abstract: A global strategy, under the coordination of the World Health Organization, is being unfolded to reduce the impact of snakebite envenoming. One of the pillars of this strategy is to ensure safe and effective treatments. The mainstay in the therapy of snakebite envenoming is the administration of animal-derived antivenoms. In addition, new therapeutic options are being explored, including recombinant antibodies and natural and synthetic toxin inhibitors. In this review, snake venom toxins are classified in terms of their abundance and toxicity, and priority Citation: Gutiérrez, J.M.; Albulescu, actions are being proposed in the search for snake venom metalloproteinase (SVMP), phospholipase L.-O.; Clare, R.H.; Casewell, N.R.; A2 (PLA2), three-finger toxin (3FTx), and serine proteinase (SVSP) inhibitors.